There is no universal best medicine for diabetes. The right drug depends on your A1C level, weight, heart and kidney health, risk of hypoglycemia, cost, and personal preferences. Metformin remains the most common first-line medication for type 2 diabetes, but newer GLP-1 receptor agonists and SGLT2 inhibitors have reshaped treatment when weight loss, heart protection, or kidney benefits are priorities.
How “Best” Is Defined
Diabetes medications are evaluated on multiple dimensions, and a drug that is best on one may be mediocre on another.
- A1C reduction — how much the drug lowers long-term blood sugar
- Weight effect — whether it causes loss, gain, or stays neutral
- Cardiovascular benefit — reduction in heart attack, stroke, heart failure
- Kidney benefit — slowing of chronic kidney disease progression
- Hypoglycemia risk — likelihood of dangerous low blood sugar
- Cost and access — monthly out-of-pocket spending
- Tolerability — side effect profile and patient comfort
The 2024 ADA Standards of Care explicitly moved away from a one-size-fits-all stepwise approach toward patient-centered selection based on these factors.
Metformin: The Proven Workhorse
Metformin has been used for decades, is available generically, and costs as little as $4 per month. It reduces glucose production in the liver and improves insulin sensitivity.
- A1C reduction: 1 to 1.5 percentage points
- Weight: neutral to slight loss
- Hypoglycemia risk: very low
- Cardiovascular benefit: likely but modest; no outcome trials as primary endpoint
- Cost: $4 to $10 per month
- Common side effects: GI upset, metallic taste (often fade in weeks)
Metformin is still a reasonable first choice for most newly diagnosed adults without advanced complications. It is also sometimes used in prediabetes, especially with a history of gestational diabetes or BMI over 35.
GLP-1 Receptor Agonists: Strongest Weight and A1C Effects
GLP-1 drugs are injectable (mostly) medications that mimic an intestinal hormone. They slow stomach emptying, stimulate insulin in response to meals, and reduce appetite centrally.
- Semaglutide (Ozempic, Rybelsus oral, Wegovy for weight loss)
- Tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 agonist
- Dulaglutide (Trulicity)
- Liraglutide (Victoza, Saxenda)
- Exenatide (Byetta, Bydureon)
A1C reductions of 1.5 to 2.0 percentage points are common, with weight loss of 10 to 20 percent. Cardiovascular trials have shown reduced rates of heart attack, stroke, and cardiovascular death with semaglutide, dulaglutide, and liraglutide. Tirzepatide cardiovascular trials are underway.
The major drawbacks are cost, often $900 to $1,300 per month without insurance, and gastrointestinal side effects during titration.
SGLT2 Inhibitors: Best for Heart and Kidneys
SGLT2 inhibitors reduce kidney reabsorption of glucose so excess spills into urine.
- Empagliflozin (Jardiance)
- Dapagliflozin (Farxiga)
- Canagliflozin (Invokana)
- Ertugliflozin (Steglatro)
A1C reduction is modest at 0.5 to 1.0 percentage points. The standout benefits are reduced heart failure hospitalization and slower kidney disease progression. Empagliflozin and dapagliflozin are approved for heart failure and chronic kidney disease regardless of diabetes status.
Side effects include genital yeast infections, urinary tract infections, and dehydration. Rare but serious risks include euglycemic ketoacidosis.
Side-by-Side Comparison
| Drug Class | A1C Drop | Weight | Heart Benefit | Monthly Cost |
|---|---|---|---|---|
| Metformin | 1.0-1.5% | Neutral | Likely modest | $4-10 |
| GLP-1 (semaglutide) | 1.5-2.0% | -10 to -15% | Yes (cardiovascular) | $900-1,000 |
| Tirzepatide | 1.8-2.4% | -15 to -20% | Under study | $1,000-1,300 |
| SGLT2 (empagliflozin) | 0.5-1.0% | -4 to -7 lbs | Yes (heart failure) | $500-600 |
| DPP-4 (sitagliptin) | 0.5-0.8% | Neutral | Neutral | $500 |
| Sulfonylurea (glipizide) | 1.0-1.5% | +2 to +5 lbs | Neutral/mild concern | $4-15 |
| Insulin (basal) | Variable, large | +5 to +10 lbs | Neutral | $25-200+ |
Choosing by Clinical Profile
If Cost Is the Main Concern
Metformin plus generic sulfonylurea is the cheapest combination, often under $15 per month. Generic SGLT2 and GLP-1 drugs do not yet exist as of 2025, though dapagliflozin generics may arrive soon.
If You Have Heart Failure or Coronary Disease
Empagliflozin or dapagliflozin (SGLT2 class) are preferred, often added to metformin. These drugs reduce heart failure hospitalizations by 20 to 30 percent regardless of A1C starting point.
If You Have Chronic Kidney Disease
SGLT2 inhibitors and GLP-1 agonists both appear kidney-protective. Dapagliflozin is FDA-approved for chronic kidney disease even without diabetes.
If Weight Loss Is a Priority
Tirzepatide produces the greatest weight loss, followed by semaglutide. Patients with BMI over 30 and A1C above 8 often benefit most from starting with one of these rather than metformin.
If Hypoglycemia Risk Is a Concern
Metformin, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 agonists rarely cause hypoglycemia alone. Sulfonylureas and insulin are the classes most likely to cause lows. Older adults and people with irregular meals should avoid sulfonylureas when possible.
If A1C Is Very High
When A1C is 9 percent or higher at diagnosis, starting with combination therapy (metformin plus a GLP-1 or SGLT2) or even insulin may be appropriate. A single drug rarely brings a high A1C to goal.
What About Type 1 Diabetes?
For type 1 diabetes, insulin is not just the best medicine, it is the only effective medicine. Modern options include rapid-acting insulins (lispro, aspart, glulisine), long-acting insulins (glargine, degludec, detemir), and pumps with or without closed-loop automation. SGLT2 inhibitors and GLP-1 agonists are sometimes used off-label as adjuncts but do not replace insulin.
Combinations That Work Well
- Metformin + GLP-1 agonist — strong A1C and weight reduction
- Metformin + SGLT2 inhibitor — cardiovascular and kidney protection
- Metformin + SGLT2 + GLP-1 — comprehensive triple therapy
- Basal insulin + GLP-1 — fixed-ratio combinations like Soliqua or Xultophy
New Options on the Horizon
The pipeline for diabetes drugs is active. Retatrutide, a triple GIP/GLP-1/glucagon agonist, showed impressive weight loss in phase 2 trials. Oral tirzepatide and other oral incretin drugs are in development. These may shift the treatment landscape further over the next few years.
How to Work With Your Doctor
The best medicine for diabetes is the one you can access, tolerate, and take consistently. Bring specific questions to your next appointment:
- What is my A1C goal, and how far am I from it?
- Given my heart and kidney health, which drug class is most beneficial?
- What will this medication cost me per month with my insurance?
- What side effects should I watch for, and when should I call?
- How often will we reassess whether this drug is working?
For more background, see our treatment hub and prediabetes overview.
The Bottom Line
There is no single best medicine for diabetes. Metformin remains a strong first choice for most adults with newly diagnosed type 2 diabetes because of its low cost and excellent safety profile. GLP-1 agonists like semaglutide and tirzepatide offer the largest A1C and weight benefits. SGLT2 inhibitors shine when heart failure or kidney disease is present. Insulin remains essential for type 1 diabetes and advanced type 2. Choose the drug that matches your biggest clinical concern, fits your budget, and you can take consistently, and revisit the decision regularly with your care team.
